January 6, 2023
Peter A. Kiener, DPhil and Mary E. Wadlinger to Join LAVA Board UTRECHT, The Netherlands and PHILADELPHIA, Jan. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific